Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TLR4 | O00206 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7763088 | 0.73 | — | — | |
| SCHEMBL3000246 | 0.71 | — | — | |
| SCHEMBL10476386 | 0.64 | MEN1 (0.41) | NFE2L2 | |
| SCHEMBL24966387 | 0.64 | TLR4 (0.36) | NFE2L2NPC1MAPTRAB9ATLR4 | |
| SCHEMBL16803982 | 0.64 | TLR4 (0.34) | TLR4 | |
| SCHEMBL14275775 | 0.63 | CYP19A1 (0.40) | MAPT | |
| SCHEMBL11308573 | 0.62 | RAB9A (0.47) | NFE2L2NPC1MAPTRAB9ATLR4 | |
| SCHEMBL11308580 | 0.62 | RAB9A (0.47) | NFE2L2NPC1MAPTRAB9ATLR4 | |
| SCHEMBL873797 | 0.61 | TLR4 (0.32) | NFE2L2NPC1MAPTRAB9ATLR4 | |
| SCHEMBL9510304 | 0.61 | NPC1 (0.43) | NFE2L2NPC1MAPTRAB9ATLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107320531-B | Traditional Chinese medicine active component for external treatment of cold internal disease and production method thereof | 广西源安堂药业有限公司 | 2020-09-08 | — | — | CN | disclosed |
| CN-106061474-B | Method for treating alopecia using monoterpenoids | 赛尔米德有限公司 | 2020-03-03 | — | — | CN | disclosed |
| EP-3079679-B1 | METHOD OF TREATMENT OF ALOPECIA WITH MONOTERPENOIDS | CELLMID LTD (AU) | 2019-08-14 | — | — | EP | disclosed |
| US-20180360792-A1 | Method of Treatment of Alopecia with Monoterpenoids | Cellmid Limited (AU) | 2018-12-20 | — | — | US | disclosed |
| US-20160374979-A1 | Method of Treatment of Alopecia with Monoterpenoids | Cellmid Limited (AU) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160374979-A1 | Method of Treatment of Alopecia with Monoterpenoids | FGF1, FGF2, FGFR1 | NFE2L2 628/4885NPC1 3237/4885MAPT 2003/4885 |
| US-20180360792-A1 | Method of Treatment of Alopecia with Monoterpenoids | FGF1, FGF2, FGFR1 | NFE2L2 645/4885NPC1 3390/4885MAPT 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.